Siegfried Holding Ltd - Asset Resilience Ratio
Siegfried Holding Ltd (SFZN) has an Asset Resilience Ratio of 1.79% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Siegfried Holding Ltd's Asset Resilience Ratio has changed over time. Check Siegfried Holding Ltd (SFZN) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Siegfried Holding Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SFZN company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF34.49 Million | 1.75% |
| Short-term Investments | CHF860.00K | 0.04% |
| Total Liquid Assets | CHF35.35 Million | 1.79% |
Asset Resilience Insights
- Limited Liquidity: Siegfried Holding Ltd maintains only 1.79% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Siegfried Holding Ltd Industry Peers by Asset Resilience Ratio
Compare Siegfried Holding Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089 |
Drug Manufacturers - Specialty & Generic | 10.89% |
|
Akums Drugs and Pharmaceutical
NSE:AKUMS |
Drug Manufacturers - Specialty & Generic | 28.08% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Tibet Weixinkang Medicine Co Ltd
SHG:603676 |
Drug Manufacturers - Specialty & Generic | 40.81% |
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Siegfried Holding Ltd (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Siegfried Holding Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.05% | CHF39.61 Million ≈ $50.08 Million |
CHF1.93 Billion ≈ $2.44 Billion |
-0.99pp |
| 2023-12-31 | 3.04% | CHF56.63 Million ≈ $71.59 Million |
CHF1.86 Billion ≈ $2.35 Billion |
-2.07pp |
| 2022-12-31 | 5.11% | CHF91.62 Million ≈ $115.83 Million |
CHF1.79 Billion ≈ $2.27 Billion |
+5.09pp |
| 2021-12-31 | 0.02% | CHF345.00K ≈ $436.17K |
CHF1.67 Billion ≈ $2.11 Billion |
+0.02pp |
| 2020-12-31 | 0.00% | CHF30.00K ≈ $37.93K |
CHF1.24 Billion ≈ $1.57 Billion |
0.00pp |
| 2019-12-31 | 0.00% | CHF30.00K ≈ $37.93K |
CHF1.17 Billion ≈ $1.48 Billion |
0.00pp |
| 2018-12-31 | 0.00% | CHF30.00K ≈ $37.93K |
CHF1.10 Billion ≈ $1.39 Billion |
0.00pp |
| 2017-12-31 | 0.00% | CHF30.00K ≈ $37.93K |
CHF1.07 Billion ≈ $1.35 Billion |
-0.04pp |
| 2016-12-31 | 0.05% | CHF471.00K ≈ $595.47K |
CHF1.02 Billion ≈ $1.29 Billion |
-0.42pp |
| 2011-12-31 | 0.46% | CHF2.08 Million ≈ $2.62 Million |
CHF448.00 Million ≈ $566.39 Million |
-0.06pp |
| 2010-12-31 | 0.52% | CHF2.43 Million ≈ $3.07 Million |
CHF464.05 Million ≈ $586.69 Million |
+0.51pp |
| 2005-12-31 | 0.01% | CHF86.00K ≈ $108.73K |
CHF677.52 Million ≈ $856.57 Million |
-- |
About Siegfried Holding Ltd
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. The company offers drug substances, including exclusive synthesis that manufactures custom APIs. It also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pa… Read more